Please assess the completion status of the following clinical trial:

Trial Title: Anti-Inflammatory Effects of Pioglitazone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects between the ages of 35 and 85 years~* Subjects with impaired glucose tolerance and type 2 diabetes, who had atherosclerosis detected by carotid ultrasound and/or CT~* Subjects who had vascular FDG uptake by FDG-PET~Exclusion Criteria:~* Subjects with insulin treatment~* Subjects with uncontrolled diabetes, hypertension, symptomatic coronary artery disease, symptomatic cerebrovascular disease~* Subjects taking more than three antidiabetic medications~* Subjects taking anti-platelet, statins, antidiabetic agents, thiazolidinediones (TZDs) within 8 weeks prior to randomization~* Subjects with cardiac failure (New York Heart Association Class \> III) or left ventricular dysfunction (LVEF \< 40%)~* Subjects with systemic disorders such as active inflammatory, liver, renal, hematopoietic, and malignant disease

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): up to 30 mg pioglitazone, tablet, orally, once daily
- 2 (Type: ACTIVE_COMPARATOR): up to 4 mg/day glimepiride, tablet, orally, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).